Literature DB >> 9029414

A preliminary study of possible psychoactive effects of intravenous forskolin in depressed and schizophrenic patients. Short communication.

Y Bersudsky1, M Kotler, M Shifrin, R H Belmaker.   

Abstract

Forskolin is a unique activator of adenylate cyclase that bypasses membrane receptors and directly raised levels of the second messenger cyclic AMP. Depressed patients and schizophrenic patients with negative symptoms have been reported to have reduced cyclic AMP levels. In the first study of forskolin in psychiatry, we gave iv forskolin in a 75 minute infusion to four depressed and five schizophrenic patients. All four depressed patients showed a transient mood elevation or stimulation, as did two of the five schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9029414     DOI: 10.1007/BF01271261

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  15 in total

1.  Clinical correlates of CSF cyclic nucleotides in schizophrenia.

Authors:  J Zohar; J Biederman; R Rimon; R Ebstein; R H Belmaker
Journal:  Am J Psychiatry       Date:  1978-02       Impact factor: 18.112

Review 2.  Dysbalance of neuronal second messenger function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors.

Authors:  H Wachtel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Urinary excretion of cyclic AMP and manic-depressive psychosis.

Authors:  B L Brown; J G Salway; J D Albano; R P Hullin; R P Ekins
Journal:  Br J Psychiatry       Date:  1972-04       Impact factor: 9.319

4.  Amphetamine effects in man: paradoxical drowsiness and lowered electrical brain acitivity (CNV).

Authors:  J J Tecce; J O Cole
Journal:  Science       Date:  1974-08-02       Impact factor: 47.728

5.  Effects of forskolin on spontaneous behavior, rectal temperature and brain cAMP levels of rats: interaction with rolipram.

Authors:  H Wachtel; P A Löschmann; H H Schneider; K J Rettig
Journal:  Neurosci Lett       Date:  1987-05-06       Impact factor: 3.046

6.  The positive inotropic-acting forskolin, a potent adenylate cyclase activator.

Authors:  H Metzger; E Lindner
Journal:  Arzneimittelforschung       Date:  1981

7.  Cyclic nucleotides in mental disorder.

Authors:  R H Belmaker; J Zohar; R P Ebstein
Journal:  Adv Cyclic Nucleotide Res       Date:  1980

8.  Lack of effectiveness of forskolin or inositol as antidote in lithium toxicity. Short note.

Authors:  Z Kaplan; G Schreiber; R H Belmaker
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.

Authors:  K B Seamon; W Padgett; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  Receptors, adenylate cyclase, depression, and lithium.

Authors:  R H Belmaker
Journal:  Biol Psychiatry       Date:  1981-04       Impact factor: 13.382

View more
  3 in total

1.  The effect of acute and chronic lithium on forskolin-induced reduction of rat activity.

Authors:  Y Bersudsky; Y Patishi; J Bitsch Jensen; A Mørk; O Kofman; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Adenylyl Cyclase (AC) Mediates the Antidepressant-Like Effects of Tropisetron on a Mouse Model of Maternal Separation Stress.

Authors:  Ali Hosseinzadeh; Shakiba Nasiri Boroujeni; Elham Saghaei; Zahra Loriooini; Saeid Habibian Dehkordi; Shima Balali-Dehkordi; Mohammad Rahimi-Madiseh; Hossein Amini-Khoei
Journal:  Depress Res Treat       Date:  2021-04-22

3.  The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM.

Authors:  Virginie Follin-Arbelet; Kristine Misund; Elin Hallan Naderi; Hege Ugland; Anders Sundan; Heidi Kiil Blomhoff
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.